New cancer drug shows promise in early trial

NCT ID NCT02952248

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs that the drug might shrink tumours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 754091 (ezabenlimab), an immunotherapy drug
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumours that have not responded to other therapies.
What could go wrong: This is an early Phase I trial focused on safety and dosing, not on proving effectiveness. The drug may not shrink tumours or could cause significant side effects. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

Centre Hospitalier de l'Universite de Montreal (CHUM)

Montreal, Quebec, H2X 0A9, Canada
Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Greenville Health System

Greenville, South Carolina, 29605, United States
Ingalls Memorial Hospital

Harvey, Illinois, 60426, United States
Juravinski Cancer Centre - Hamilton Health Sciences

Hamilton, Ontario, L8V 5C2, Canada
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Sarah Cannon Research Institute

London, W1G 6AD, United Kingdom
Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
Tennessee Oncology, PLLC

Nashville, Tennessee, 37203, United States
The Christie Hospital

Manchester, M20 4BX, United Kingdom
The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.